| Title |
Tumor-associated myeloid cells as guiding forces of cancer cell stemness
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2017
|
| DOI | 10.1007/s00262-017-1997-8 |
| Pubmed ID | |
| Authors |
Antonio Sica, Chiara Porta, Alberto Amadori, Anna Pastò |
| Abstract |
Due to their ability to differentiate into various cell types and to support tissue regeneration, stem cells simultaneously became the holy grail of regenerative medicine and the evil obstacle in cancer therapy. Several studies have investigated niche-related conditions that favor stemness properties and increasingly emphasized their association with an inflammatory environment. Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are major orchestrators of cancer-related inflammation, able to dynamically express different polarized inflammatory programs that promote tumor outgrowth, including tumor angiogenesis, immunosuppression, tissue remodeling and metastasis formation. In addition, these myeloid populations support cancer cell stemness, favoring tumor maintenance and progression, as well as resistance to anticancer treatments. Here, we discuss inflammatory circuits and molecules expressed by TAMs and MDSCs as guiding forces of cancer cell stemness. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 23% |
| Student > Master | 5 | 11% |
| Professor | 4 | 9% |
| Student > Bachelor | 3 | 6% |
| Student > Doctoral Student | 3 | 6% |
| Other | 7 | 15% |
| Unknown | 14 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 17% |
| Medicine and Dentistry | 7 | 15% |
| Immunology and Microbiology | 5 | 11% |
| Agricultural and Biological Sciences | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 4 | 9% |
| Unknown | 17 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2017.
All research outputs
#15,330,390
of 23,577,654 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,113
of 2,948 outputs
Outputs of similar age
#186,231
of 311,109 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#38
of 51 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,948 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,109 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.